International law firm Clifford Chance has advised, as consortium counsel, an investors’ consortium comprising OMERS Infrastructure, Goldman Sachs Asset Management and AXA IM Alts on the signing of an agreement to acquire amedes Group, a leading provider of medical diagnostics services in Germany, Belgium and Austria, from current investor Antin Infrastructure Partners.

OMERS and Goldman Sachs will each hold 37.5 per cent, AXA 25 percent of the stakes in amedes. The transaction remains subject to customary regulatory approvals and is expected to close before year end.

Amedes is conducting more than 400,000 medical analyses per day for the healthcare industry across its more than 75 laboratories and specialty medicine sites across Germany, Belgium and Austria. Under the consortium’s ownership, amedes will continue to expand its leading market position in integrated specialty diagnostics, particularly in gynaecology, endocrinology and fertility medicine. Other growth areas include genetics, rheumatology and oncology.

Anselm Raddatz, Corporate partner and Private Equity Group Lead at Clifford Chance in Germany, comments: “Infrastructure investors are increasingly focusing on the healthcare industry with its essential services, sustainable growth potential and resilient cash flows. Amedes stands out as a market leader in this field. We are very pleased to have been able to provide this powerful investors’ consortium with our firm’s market-leading legal and sector know-how to all aspects and phases of this major cross-border transaction.”

The international Clifford Chance team advising the investors’ consortium OMERS, Goldman Sachs and AXA was led by partners Anselm Raddatz and Markus Stephanblome with senior associate Tobias Kamerling and associate Denise Rosenau (all Frankfurt/Düsseldorf), further comprising partner Toby Parkinson and senior associate Ed Holmes (both London) as well as senior associate Daniel Gutmann and associate Matthias C. Forster (both Frankfurt/Düsseldorf) (all Corporate); partner Peter Dieners with senior associates Caroline Giesen and Carolin Kemmner as well as associate Marlene Kießling (all Healthcare/Compliance, Düsseldorf); partner Marc Besen with senior associate Johannes Lüer (both Antitrust, Düsseldorf); as well as partner Dominik Engl and counsel Cord von Mandelsloh (both Tax, Frankfurt/Düsseldorf).

A team led by partner Nicholas Kinnersley with senior associate Alim Amershi and associate Raad Gorji (all London) as well as partner Steffen Schellschmidt with senior associate Philip Rosak and associate Peter Gierl (all Frankfurt) (all Global Financial Markets) advised on the transaction financing.

The due diligence team comprised partner Ines Keitel, senior associate Susanne Julis and associate Vanessa Zipperich (all Employment, Frankfurt); partner Thomas Reischauer and senior associate Amrei Fuder (both Real Estate, Frankfurt); partner Claudia Milbradt with counsel Susanne Werry, senior associate Nicolas Hohn-Hein and associate Michael Kümmel (all IP, Data Privacy) (all Frankfurt/Düsseldorf); as well as partner Xavier Remy, counsel Gert Cuppens and associate Haaike Wouters (all Corporate, Brussels).

Partner Katia Gauzés with senior associate Mélissa Kydem and associate Megi Bllaca (all Corporate, Luxembourg) provided further advice on the transaction structuring.